Low-dose Btk inhibitors selectively block platelet activation by CLEC-2

Inhibitors of Bruton tyrosine kinase (Btk) have been proposed as novel antiplatelet agents. In this study we show that low concentrations of the Btk inhibitor ibrutinib block CLEC-2-mediated activation and tyrosine phosphorylation including Syk and PLC gamma 2 in human platelets. Activation is also blocked in patients with X-linked agammaglobulinemia (XLA) caused by a deficiency or absence of Btk. In contrast, the response to GPVI is delayed in the presence of low concentrations of ibrutinib or in patients with XLA, and tyrosine phosphorylation of Syk is preserved. A similar set of results is seen with the second-generation inhibitor, acalabrutinib. The differential effect of Btk inhibition in CLEC-2 relative to GPVI signaling is explained by the positive feedback role involving Btk itself, as well as ADP- and thromboxane A(2)-mediated activation of P2Y(12) and TP receptors, respectively. This feedback role is not seen in mouse platelets and, consistent with this, CLEC-2-mediated activation is blocked by high but not by low concentrations of ibrutinib. Nevertheless, thrombosis was absent in eight out of 13 mice treated with ibrutinib. These results show that Btk inhibitors selectively block activation of human platelets by CLEC-2 relative to GPVI suggesting that they can be used at low doses in patients to target CLEC-2 in thrombo-inflammatory disease.

Automated summary

In this study, it was demonstrated that Btk inhibitors selectively block the activation of human platelets through CLEC-2 as opposed to GPVI, suggesting a potential therapeutic use at low doses in patients with thrombo-inflammatory diseases.